{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:19:20Z","timestamp":1791839960824,"version":"4.3.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,30]]},"DOI":"10.7759\/cureus.100410","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T14:11:49Z","timestamp":1767103909000},"source":"Crossref","is-referenced-by-count":1,"title":["Omalizumab Therapy for Bullous Pemphigoid: A Case Report"],"prefix":"10.7759","author":[{"given":"Adel","family":"Alsantali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema S","family":"AlZaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bader","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed K","family":"Bakhsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anhar K","family":"Zahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed I","family":"Alturkistani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1159351","article-title":"Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid","volume":"14","author":"Rosi-Schumacher M","year":"2023","unstructured":"Rosi-Schumacher M, Baker J, Waris J, Seiffert-Sinha K, Sinha AA. Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid. Front Immunol. 2023, 14:1159351. 10.3389\/fimmu.2023.1159351","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20838","article-title":"Unfolding the worldwide incidence of bullous pemphigoid: what are we missing?","volume":"186","author":"Aoki V","year":"2022","unstructured":"Aoki V, Miyamoto D. Unfolding the worldwide incidence of bullous pemphigoid: what are we missing?. Br J Dermatol. 2022, 186:386-387. 10.1111\/bjd.20838","journal-title":"Br J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2016.11.003","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai M","year":"2017","unstructured":"Amagai M, Ikeda S, Hashimoto T, et al.. A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. J Dermatol Sci. 2017, 85:77-84. 10.1016\/j.jdermsci.2016.11.003","journal-title":"J Dermatol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature","volume":"20","author":"Kremer N","year":"2019","unstructured":"Kremer N, Snast I, Cohen ES, et al.. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature. Am J Clin Dermatol. 2019, 20:209-216. 10.1007\/s40257-018-0401-6","journal-title":"Am J Clin Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu KK","year":"2014","unstructured":"Yu KK, Crew AB, Messingham KA, Fairley JA, Woodley DT. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014, 71:468-474. 10.1016\/j.jaad.2014.04.053","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928621","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review","volume":"13","author":"Cao P","year":"2022","unstructured":"Cao P, Xu W, Zhang L. Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review. Front Immunol. 2022, 13:928621. 10.3389\/fimmu.2022.928621","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.1604","article-title":"Successful treatment of bullous pemphigoid with omalizumab","volume":"148","author":"London VA","year":"2012","unstructured":"London VA, Kim GH, Fairley JA, Woodley DT. Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol. 2012, 148:1241-1243. 10.1001\/archdermatol.2012.1604","journal-title":"Arch Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13758","article-title":"Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature","volume":"30","author":"Balakirski G","year":"2016","unstructured":"Balakirski G, Alkhateeb A, Merk HF, Leverkus M, Megahed M. Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature. J Eur Acad Dermatol Venereol. 2016, 30:1778-1782. 10.1111\/jdv.13758","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.12.015","article-title":"IgE blockade in autoimmunity: omalizumab induced remission of bullous pemphigoid","volume":"198","author":"James T","year":"2019","unstructured":"James T, Salman S, Stevenson B, Bundell C, Kelly G, Nolan D, John M. IgE blockade in autoimmunity: omalizumab induced remission of bullous pemphigoid. Clin Immunol. 2019, 198:54-56. 10.1016\/j.clim.2018.12.015","journal-title":"Clin Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01919","article-title":"Effects of omalizumab on Fc\u03b5RI and IgE expression in lesional skin of bullous pemphigoid","volume":"10","author":"Seyed Jafari SM","year":"2019","unstructured":"Seyed Jafari SM, Gadaldi K, Feldmeyer L, Yawalkar N, Borradori L, Schlapbach C. Effects of omalizumab on Fc\u03b5RI and IgE expression in lesional skin of bullous pemphigoid. Front Immunol. 2019, 10:1919. 10.3389\/fimmu.2019.01919","journal-title":"Front Immunol"},{"key":"ref11","article-title":"Effective treatment for bullous pemphigoid with omalizumab [Article in Hebrew]","volume":"159","author":"Neumark M","year":"2020","unstructured":"Neumark M, Tal Y, Zlotogorski A, Molho-Pessach V. Effective treatment for bullous pemphigoid with omalizumab [Article in Hebrew]. Harefuah. 2020, 159:29-30.","journal-title":"Harefuah"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.611549","article-title":"Case Report: Combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid","volume":"11","author":"Seyed Jafari SM","year":"2020","unstructured":"Seyed Jafari SM, Feldmeyer L, Bossart S, Simon D, Schlapbach C, Borradori L. Case Report: Combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid. Front Immunol. 2020, 11:611549. 10.3389\/fimmu.2020.611549","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10748.x","article-title":"Successful management of severe infant bullous pemphigoid with omalizumab","volume":"166","author":"Dufour C","year":"2012","unstructured":"Dufour C, Souillet AL, Chaneliere C, et al.. Successful management of severe infant bullous pemphigoid with omalizumab. Br J Dermatol. 2012, 166:1140-1142. 10.1111\/j.1365-2133.2011.10748.x","journal-title":"Br J Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.874108","article-title":"Rapid disease control in first-line therapy-resistant mucous membrane pemphigoid and bullous pemphigoid with omalizumab as add-on therapy: a case series of 13 patients","volume":"13","author":"Alexandre M","year":"2022","unstructured":"Alexandre M, Bohelay G, Gille T, et al.. Rapid disease control in first-line therapy-resistant mucous membrane pemphigoid and bullous pemphigoid with omalizumab as add-on therapy: a case series of 13 patients. Front Immunol. 2022, 13:874108. 10.3389\/fimmu.2022.874108","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2020-002418","article-title":"Dramatic improvement of bullous pemphigoid with omalizumab in an elderly patient","volume":"28","author":"Navarro-Trivi\u00f1o FJ","year":"2021","unstructured":"Navarro-Trivi\u00f1o FJ, Llamas-Molina JM, Ayen-Rodriguez A, Cancela-D\u00edez B, Ruiz-Villaverde R. Dramatic improvement of bullous pemphigoid with omalizumab in an elderly patient. Eur J Hosp Pharm. 2021, 28:350-352. 10.1136\/ejhpharm-2020-002418","journal-title":"Eur J Hosp Pharm"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/356103-omalizumab-therapy-for-bullous-pemphigoid-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T14:11:49Z","timestamp":1767103909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/356103-omalizumab-therapy-for-bullous-pemphigoid-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.100410","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,30]]}}}